Top

Breast Cancer Research and Treatment

Published in:

01-02-2018 | Review

Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review

Authors: Leah K. Lambert, Lynda G. Balneaves, A. Fuchsia Howard, Carolyn C. Gotay

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Abstract

Background

Adjuvant endocrine therapy (AET) significantly reduces recurrence and mortality in women with breast cancer (BrCa). Despite the efficacy of AET in improving BrCa outcomes, up to 50% of women do not adhere to prescribed AET regimens. While numerous demographic and clinical predictors influence adherence and persistence, few studies have identified the patient-reported factors that influence AET adherence and persistence.

Purpose

The aim was to examine the patient-reported personal, social, and structural factors influencing BrCa survivors’ adherence and persistence with AET.

Methods

An integrative review was undertaken wherein PubMed, Medline, CINAHL, Embase, and PsycINFO databases were searched using keyword descriptors and database subject headings. Inclusion criteria included quantitative or qualitative peer-reviewed studies written in English that assessed AET adherence and/or persistence through objective measurement or self-report and included patient-reported factors found to influence adherence and/or persistence. The data extracted from eligible studies were entered into a matrix, and systematically compared and iteratively analyzed using relational autonomy as an organizing theoretical framework.

Results

A total of 43 manuscripts (9 qualitative and 34 quantitative) were reviewed. Several personal, social, and structural factors were identified that influenced AET adherence and persistence, including side effects, necessity beliefs, self-efficacy, the patient–healthcare provider relationship, social support, and continuity of follow-up care.

Conclusions

An increasing number of studies have focused on identifying the patient-reported factors that influence AET adherence and persistence. This review highlights important personal, social, and structural factors that act as facilitators and barriers in adhering to and persisting with long-term AET. Acknowledging and addressing these factors is key to providing women with the care needed to improve suboptimal adherence and persistence.

International Agency for Research on Cancer (2012) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792. https://doi.org/10.1097/01.ogx.0000201966.23445.91 CrossRefPubMed

Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796. https://doi.org/10.1200/JCO.2009.26.3756 CrossRefPubMedPubMedCentral

Hershman D, Shao T, Kushi L et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537. https://doi.org/10.1007/s10549-010-1132-4 CrossRefPubMed

Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269. https://doi.org/10.1200/JCO.2013.54.2258 CrossRefPubMedPubMedCentral

Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816. https://doi.org/10.1016/S0140-6736(12)61963-1 CrossRefPubMedPubMedCentral

Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128. https://doi.org/10.1200/JCO.2009.25.9655 CrossRefPubMedPubMedCentral

Owusu C, Buist DSM, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549–555. https://doi.org/10.1200/JCO.2006.10.1022 CrossRefPubMed

van Herk-Sukel MPP, van de Poll-Franse LV, Voogd AC et al (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122:843–851. https://doi.org/10.1007/s10549-009-0724-3 CrossRefPubMed

10.

Murphy CC, Bartholomew LK, Carpentier MY et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134:459–478. https://doi.org/10.1007/s10549-012-2114-5 CrossRefPubMedPubMedCentral

11.

Gotay C, Dunn J (2011) Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res 11:709–715. https://doi.org/10.1586/erp.11.80 CrossRefPubMed

12.

Chlebowski RT, Geller ML (2007) Adherence to endocrine therapy for breast cancer. Oncology 71:1–9. https://doi.org/10.1159/000100444 CrossRef

13.

Banning M (2012) Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl) 21:10–19. https://doi.org/10.1111/j.1365-2354.2011.01295.x CrossRef

14.

Whittemore R, Knafl K (2005) The integrative review: updated methodology. J Adv Nurs 52:546–553. https://doi.org/10.1111/j.1365-2648.2005.03621.x CrossRefPubMed

15.

Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467. https://doi.org/10.1016/S0140-6736(97)11423-4 CrossRef

16.

Van Liew JR, Christensen AJ, de Moor JS (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8:521–531. https://doi.org/10.1007/s11764-014-0374-2 CrossRefPubMed

17.

Cahir C, Guinan E, Dombrowski SU et al (2015) Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I–III breast cancer: a systematic review and meta-analysis. Patient Educ Couns 98:1524–1539. https://doi.org/10.1016/j.pec.2015.05.013 CrossRef

18.

Wuensch P, Hahne A, Haidinger R et al (2015) Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor? J Cancer Res Clin Oncol 141:55–60. https://doi.org/10.1007/s00432-014-1779-z CrossRefPubMed

19.

World Health Organization (2003) Adherence to long-term therapies: evidence for action. WHO, Geneva

20.

U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79. https://doi.org/10.1186/1477-7525-4-79 CrossRef

21.

Howell D, Fitch M, Bakker D et al (2013) Core domains for a person-focused outcome measurement system in cancer (PROMS-cancer core) for routine care: a scoping review and Canadian delphi consensus. Value Health 16:76–87. https://doi.org/10.1016/j.jval.2012.10.017 CrossRefPubMed

22.

Howell D, Molloy S, Wilkinson K et al (2015) Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 26:1846–1858. https://doi.org/10.1093/annonc/mdv181 CrossRefPubMed

23.

Whittemore R (2005) Combining evidence in nursing research: methods and implications. Nurs Res 54:56–62. https://doi.org/10.1097/00006199-200501000-00008 CrossRefPubMed

24.

Burns N (1989) Standards for qualitative research. Nurs Sci Q 2:44–52. https://doi.org/10.1177/089431848900200112 CrossRefPubMed

25.

Sherwin S (1998) A relational approach to autonomy in health care. In: Sherwin S (ed) Politics of women’s health. Exploring agency and autonomy. Temple University Press, Philadelphia, pp 19–47

26.

Friese CR, Pini TM, Li Y et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138:931–939. https://doi.org/10.1007/s10549-013-2499-9 CrossRefPubMedPubMedCentral

27.

Bradley CJ, Dahman B, Jagsi R et al (2015) Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancer. Breast Cancer Res Treat 154:417–422. https://doi.org/10.1007/s10549-015-3630-x CrossRefPubMedPubMedCentral

28.

Fink AK, Gurwitz J, Rakowski W et al (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309–3315. https://doi.org/10.1200/JCO.2004.11.064 CrossRefPubMed

29.

Lash TL, Fox MP, Westrup JL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–220. https://doi.org/10.1007/s10549-006-9193-0 CrossRefPubMed

30.

Cluze C, Rey D, Huiart L et al (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23:882–890. https://doi.org/10.1093/annonc/mdr330 CrossRefPubMed

31.

Huiart L, Bouhnik A-D, Rey D et al (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer 48:1939–1946. https://doi.org/10.1016/j.ejca.2012.03.004 CrossRefPubMed

32.

Wouters H, Stiggelbout AM, Bouvy ML et al (2014) Endocrine therapy for breast cancer: assessing an array of women’s treatment experiences and perceptions, their perceived self-efficacy and nonadherence. Clin Breast Cancer 14(460–467):e2. https://doi.org/10.1016/j.clbc.2014.04.005

33.

Wouters H, Maatman GA, Van Dijk L et al (2013) Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. Ann Oncol 24:2324–2329. https://doi.org/10.1093/annonc/mdt195 CrossRefPubMed

34.

Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145:525–534. https://doi.org/10.1007/s10549-014-2961-3 CrossRefPubMed

35.

Bright EE, Petrie KJ, Partridge AH, Stanton AL (2016) Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Res Treat 158:243–251. https://doi.org/10.1007/s10549-016-3871-3 CrossRefPubMed

36.

Chim K, Xie SX, Stricker CT et al (2013) Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 13:401. https://doi.org/10.1186/1471-2407-13-401 CrossRefPubMedPubMedCentral

37.

Brier MJ, Chambless DL, Gross R et al (2017) Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors. Cancer 123:169–176. https://doi.org/10.1002/cncr.30318 CrossRefPubMed

38.

Kadakia KC, Snyder CF, Kidwell KM et al (2016) Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist 21:539–546. https://doi.org/10.1634/theoncologist.2015-0349 CrossRefPubMedPubMedCentral

39.

Kidwell KM, Harte SE, Hayes DF et al (2014) Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 120:2403–2411. https://doi.org/10.1002/cncr.28756 CrossRefPubMedPubMedCentral

40.

Henry NL, Azzouz F, Desta Z et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936–942. https://doi.org/10.1200/JCO.2011.38.0261 CrossRefPubMedPubMedCentral

41.

Liu Y, Malin JL, Diamant AL et al (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication. Breast Cancer Res Treat 137:829–836. https://doi.org/10.1007/s10549-012-2387-8 CrossRefPubMed

42.

Kahn KL, Schneider EC, Malin JL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45:431–439CrossRefPubMed

43.

Quinn EM, Fleming C, O’Sullivan MJ (2016) Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy. Ir J Med Sci 185:383–392. https://doi.org/10.1007/s11845-015-1307-4 CrossRefPubMed

44.

Kimmick G, Edmond SN, Bosworth HB et al (2015) Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast 24:630–636. https://doi.org/10.1016/j.breast.2015.06.010 CrossRefPubMedPubMedCentral

45.

Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8:e149–e157. https://doi.org/10.1200/JOP.2012.000543 CrossRefPubMedPubMedCentral

46.

Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer Care (Engl) 42:2271–2276. https://doi.org/10.1016/j.ejca.2006.03.004 CrossRef

47.

Kyvernitakis I, Ziller V, Hars O et al (2014) Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric 17:252–259. https://doi.org/10.3109/13697137.2013.819327 CrossRefPubMed

48.

Bender CM, Gentry AL, Brufsky AM et al (2014) Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 41:274–285. https://doi.org/10.1188/14.ONF.274-285 CrossRefPubMedPubMedCentral

49.

Hadji P, Jackisch C, Bolten W et al (2014) COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol 25:372–377. https://doi.org/10.1093/annonc/mdt513 CrossRefPubMed

50.

Demissie S, Silliman RA, Lash TL et al (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322–328. https://doi.org/10.1200/JCO.2001.19.2.322 CrossRefPubMed

51.

Brett J, Fenlon D, Boulton M et al (2016) Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care (Engl). https://doi.org/10.1111/ecc.12601

52.

Hershman DL, Kushi LH, Hillyer GC et al (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 157:133–143. https://doi.org/10.1007/s10549-016-3788-x CrossRefPubMedPubMedCentral

53.

Wickersham KE, Sereika SM, Bender CM (2013) Pretreatment predictors of short-term nonadherence to oral hormonal therapy for women with breast cancer. Nurs Res 62:243–251. https://doi.org/10.1097/NNR.0b013e318298fd70 CrossRefPubMedPubMedCentral

54.

Huiart L, Bouhnik A-DD, Rey D et al (2013) Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS ONE 8:e81677. https://doi.org/10.1371/journal.pone.0081677 CrossRefPubMedPubMedCentral

55.

Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102. https://doi.org/10.1016/j.pec.2004.10.005 CrossRefPubMed

56.

Arriola KRJ, Mason TA, Bannon KA et al (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 95:98–103. https://doi.org/10.1016/j.pec.2013.12.019 CrossRef

57.

Heisig SR, Shedden-Mora MC, von Blanckenburg P et al (2015) Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. Psychooncology 24:130–137. https://doi.org/10.1002/pon.3611 CrossRefPubMed

58.

Albert U-S, Zemlin C, Hadji P et al (2011) The impact of breast care nurses on patients’ satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. Breast Care 6:221–226. https://doi.org/10.1159/000329006 CrossRefPubMedPubMedCentral

59.

Cahir C, Dombrowski SU, Kelly CM et al (2015) Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer 23:3115–3130. https://doi.org/10.1007/s00520-015-2685-x CrossRefPubMed

60.

Wells KJ, Pan TM, Vázquez-Otero C et al (2016) Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer 24:4123–4130. https://doi.org/10.1007/s00520-016-3229-8 CrossRefPubMedPubMedCentral

61.

Wickersham K, Happ MB, Bender CM (2012) “Keeping the boogie man away”: medication self-management among women receiving anastrozole therapy. Nurs Res Pract 2012:1–9. https://doi.org/10.1155/2012/462121 CrossRef

62.

Pellegrini I, Sarradon-Eck A, Soussan PB et al (2010) Women’s perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of view. Psychooncology 19:472–479. https://doi.org/10.1002/pon.1593 CrossRefPubMed

63.

Brauer ER (2016) “Winging it”: how older breast cancer survivors persist with aromatase inhibitor treatment. J Oncol Pract 12:e991–e1000. https://doi.org/10.1200/JOP.2016.011767 CrossRefPubMedPubMedCentral

64.

Farias AJ, Ornelas IJ, Hohl SD et al (2017) Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. Support Care Cancer 25:75–83. https://doi.org/10.1007/s00520-016-3389-6 CrossRefPubMed

65.

Harrow A, Dryden R, McCowan C et al (2014) A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer. BMJ Open 4:e005285. https://doi.org/10.1136/bmjopen-2014-005285 CrossRefPubMedPubMedCentral

66.

Simon R, Latreille J, Matte C et al (2014) Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg 57:26–32. https://doi.org/10.1503/cjs.006211 CrossRefPubMedPubMedCentral

67.

Wouters H, van Geffen ECG, Baas-Thijssen MC et al (2013) Disentangling breast cancer patients’ perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence. Breast 22:661–666. https://doi.org/10.1016/j.breast.2013.05.005 CrossRefPubMed

68.

Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107:167–180. https://doi.org/10.1007/s10549-007-9548-1 CrossRefPubMed

69.

Niravath P (2013) Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 24:1443–1449. https://doi.org/10.1093/annonc/mdt037 CrossRefPubMed

70.

Walker EM, Rodriguez AI, Kohn B et al (2010) Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 28:634–640. https://doi.org/10.1200/JCO.2009.23.5150 CrossRefPubMed

71.

Hadji P, Blettner M, Harbeck N et al (2013) The patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. https://doi.org/10.1093/annonc/mds653

72.

Neven P, Markopoulos C, Tanner M et al (2014) The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast 23:393–399. https://doi.org/10.1016/j.breast.2014.02.009 CrossRefPubMed

73.

Ziller V, Kyvernitakis I, Knöll D et al (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment-the COMPAS study. BMC Cancer 13:407. https://doi.org/10.1186/1471-2407-13-407 CrossRefPubMedPubMedCentral

74.

Kirchner TR, Shiffman S (2013) Ecological momentary assessment. In: Wiley-Blackwell handbook of addiction psychopharmacology. 10.1002/9781118384404.ch20

Title: Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review
Authors: Leah K. Lambert
Lynda G. Balneaves
A. Fuchsia Howard
Carolyn C. Gotay
Publication date: 01-02-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4561-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Does the elevation of CAMLs predict metastatic breast cancer patients’ survival?

Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery

Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer

Reclassifying HER2-equivocal disease

The value of embedding: integrated palliative care for patients with metastatic breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer